Queremos expresar nuestra más sincera solidaridad y apoyo incondicional a todos los afectados por las devastadoras inundaciones en Valencia. Nuestros pensamientos están con todas las personas que atraviesan estos momentos difíciles, y es importante recordar, aún pasados los días, que no están solos. En #Oxolife, siempre nos hemos sentido respaldados y acompañados por grandes profesionales que colaboran con nosotros desde Valencia y sabemos que están haciendo el máximo esfuerzo para retornar a la actividad lo antes posible; queremos transmitirles toda nuestra fuerza y aliento en este camino de recuperación.
OXOLIFE
Biotecnología
Barcelona, Barcelona 2815 seguidores
Enhancing embryo implantation. Improving women’s fertility
Sobre nosotros
Oxolife is a biotechnology company dedicated to enhancing female fertility, with a focus on embryo implantation in women undergoing assisted reproductive technologies (ART). We are developing OXO-001, a first-in-class, non-hormonal oral treatment that directly targets the endometrium, enhancing embryo implantation and increasing Live Birth Rates (LBR). This innovative approach addresses an unmet medical need, as no drug currently exists to specifically increase embryo implantation rates, accounting for 65% Embryo Transfer failures. OXO-001 stands out due to its unique mechanism of action, offering a groundbreaking solution in the fertility space. Following the completion of our Phase II clinical trial, the results have been highly promising, demonstrating a strong balance of efficacy and safety, increasing LBR by 6.9%. These findings position Oxolife to move confidently toward the final stages of clinical development to bring this essential treatment to market, backed by a portfolio of global patents. In addition to our work with OXO-001, we are conducting research aimed at restoring fertility in women affected by polycystic ovarian syndrome (PCOS), a common cause of infertility. Our vision is to improve the chances of live birth for women with infertility, significantly reducing the stress and financial burden associated with infertility treatments for women and couples worlwide. Oxolife is led by Agnès Arbat, MD (Co-founder and CEO), and Ignasi Canals, PhD in Biochemistry (Co-founder and CSO). Together with Oxolife a multidisciplinary, diverse, and high-skilled team, supported by an exceptional international Advisory Board, that has built a robust network of partnerships with key fertility clinics and research institutions, we bring extensive experience in women’s health, pharmaceutical innovation, and drug development.
- Sitio web
-
http://www.oxolife.com
Enlace externo para OXOLIFE
- Sector
- Biotecnología
- Tamaño de la empresa
- De 2 a 10 empleados
- Sede
- Barcelona, Barcelona
- Tipo
- De financiación privada
- Fundación
- 2013
- Especialidades
- R&D, fertility, Human reproduction, Biotechnology, Healthcare, Animal Health y Livestock
Ubicaciones
-
Principal
Cómo llegar
C/ Riu de l’Or
12 Bajos 2ª
Barcelona, Barcelona 08034, ES
Empleados en OXOLIFE
Actualizaciones
-
Oxolife CEO, Agnès Arbat, is in Boston participating in the first-ever Programa Desafía Boston, powered by Richi Entrepreneurs! We look forward to the insights, growth, and strategic partnerships that will come from this unique experience in Boston. Stay tuned for updates on this exciting journey! #DesafíoBoston#Biotech#Innovation#ICEX#StartupJourney#BostonChallenge#GlobalExpansion #BiotechInnovation#growwithus#fertility
The first-ever Programa Desafía Boston, powered by Richi Entrepreneurs, is officially underway, and we couldn’t be more excited to welcome this incredible cohort! Over the next two weeks, these eleven pioneering biotech startups will dive deep into Boston’s vibrant innovation ecosystem, soaking up insights, forging new connections, and exploring opportunities that will take their ventures to the next level. To our amazing participants: we’re thrilled to have you here and can’t wait to see the impact you’ll make! Let’s make this an unforgettable journey! 🌎✨ Meet the trailblazing startups: 🚀 ARRAYS FOR CELL NANODEVICES, SL - A4CELL (Elena Rivas, Leon Wert-Lamas) 🚀 BioClonal (Paula Garfella Lorente, Jessika Valero Gonzalez) 🚀 Duponte Group (María Camila Puentes) 🚀 Inhibitec Anticuerpos, S.L. (Victoria Casado Medrano) 🚀 MIMO Biosciences (Ricardo Perez Merino) 🚀 Miramoon Pharma (Amalia Capilla, Ana Espinosa) 🚀 Nanological (Blanca Caballero, PhD, Daniel Ramos) 🚀 OXOLIFE (Agnès Arbat) 🚀 PlusVitech (Vicente Salinas Martín, Fran Guillén) 🚀 STAb Therapeutics (Carolina Pola, Belén Blanco Durango) 🚀 WorldPathol (Iván José Galindo Cardiel) Here’s to an inspiring edition of Desafía Boston! Let’s get started! 💥 ICEX https://lnkd.in/g7ejZUAS
-
-
On Thursday, 10th October 2024, our CEO, Agnès Arbat, will attend #Optimum's 16th Annual Healthcare Investor Conference in London—one of Europe's leading thought leadership events. We are excited to engage with executives and investors from the healthcare sector and discuss the trends poised to shape the industry's future. #Annual Healthcare Investor Conference #fertilityjourney#womenshealth#growwithus#fertility
-
-
OXOLIFE ha compartido esto
🚀 Exciting News! 🚀 OXOLIFE has been selected by ICEX for the inaugural edition of the "Desafío Boston" an immersion and support program aimed at leading Spanish startups and companies with a high innovative and technological component in the biotech sector. This prestigious program offers an incredible opportunity for us to connect with key players in the U.S. biotech ecosystem, gain invaluable insights, and continue driving innovation on a global scale. A big thank you to ICEX, Richi Entrepreneurs and all the program organizers for this recognition. #DesafíoBoston #Biotech #Innovation #ICEX #StartupJourney #BostonChallenge #GlobalExpansion #BiotechInnovation# #growwithus #fertility
-
-
🚀 Exciting News! 🚀 OXOLIFE has been selected by ICEX for the inaugural edition of the "Desafío Boston" an immersion and support program aimed at leading Spanish startups and companies with a high innovative and technological component in the biotech sector. This prestigious program offers an incredible opportunity for us to connect with key players in the U.S. biotech ecosystem, gain invaluable insights, and continue driving innovation on a global scale. A big thank you to ICEX, Richi Entrepreneurs and all the program organizers for this recognition. #DesafíoBoston #Biotech #Innovation #ICEX #StartupJourney #BostonChallenge #GlobalExpansion #BiotechInnovation# #growwithus #fertility
-
-
Yesterday Rosa & Marta reached an exiting milestone, 4 years at OXOLIFE 🚀 From day one, they have been an integral part of our journey, bringing passion, dedication, and innovation to everything they pursue. Thanks to everyone who has accompanied us on this amazing journey . Together, we continue pushing the boundaries of science and improving lives. #WomensHealth#Fertility#growwithus
-
-
OXOLIFE ha compartido esto
We are grateful that our Phase II clinical trial has been selected among the most clinically relevant studies from ESHRE 2024, as part of the REPROFACT 2024 report. Our heartfelt thanks to the REPROFACT Network and #ESHRE for featuring our study in the 2024 Report, and a special thanks to Prof. William Leight Ledger for your valuable expert insights. #Oxolife is currently in the process of fundraising and exploring collaborations with pharmaceutical companies to accelerate the development of OXO-001 and confirm the promising results from our Phase II study. We are excited about advancing clinical knowledge and sharing our progress. Our commitment remains strong to furthering the development of OXO-001, bringing renewed hope to both patients and the scientific community. Check it out at: https://reprofacts.com #WomensHealth#Fertility#growwithus
-
-
We are grateful that our Phase II clinical trial has been selected among the most clinically relevant studies from ESHRE 2024, as part of the REPROFACT 2024 report. Our heartfelt thanks to the REPROFACT Network and #ESHRE for featuring our study in the 2024 Report, and a special thanks to Prof. William Leight Ledger for your valuable expert insights. #Oxolife is currently in the process of fundraising and exploring collaborations with pharmaceutical companies to accelerate the development of OXO-001 and confirm the promising results from our Phase II study. We are excited about advancing clinical knowledge and sharing our progress. Our commitment remains strong to furthering the development of OXO-001, bringing renewed hope to both patients and the scientific community. Check it out at: https://reprofacts.com #WomensHealth#Fertility#growwithus
-
-
We are extremely proud to announce that our CEO Agnès Arbat has successfully made the finalist roster for the prestigious 2024 European Lifestars Awards - Celebrating Life Science Leaders in the Women-Led Business of the Year category –. Winner will be announced in London during Investival Showcase , the kick off to Jefferies week on November 18th ⭐ !! We would also like to extend our congratulations to the other outstanding finalists. Best luck to all Learn more about Oxolife --> https://oxolife.com/ #lifestarsawards #LSX #WomensHealth #Fertility #growwithus
-
-
OXOLIFE ha compartido esto
We are thrilled that so many of Optimum’s brilliant clients have been nominated for LSX - partnering for Life Science eXecutives Lifestars Awards 2024! Congratulations to all the nominees. We are looking forward to seeing you at the Awards Ceremony on the 18th of November 🥂
-
Páginas similares
Buscar empleos
Financiación
OXOLIFE
3 rondas en total
![]()
Ministry of Science and Innovation of Spain
Ver más información en Crunchbase
Última ronda
Otorgar
Enlace externo a Crunchbase para la última ronda de financiación
2.549.801,00 US$
Inversores